Myriad Genetics Q4 2025 earnings preview
This article is a Q4 2025 earnings preview for Myriad Genetics. It contains no further information about the company's financial outlook or upcoming report. The content is extremely brief and lacks substantive detail.
Myriad Genetics Inc expected to post a loss of 1 cent a share - Earnings Preview
Myriad Genetics Inc (MYGN) is projected to report a loss of 1 cent per share in its upcoming earnings announcement. This information comes from a Refinitiv earnings preview. The article is a brief financial news item by Reuters.
Myriad Genetics (MYGN) Publishes Promising Validation of FirstGene Prenatal Test
Myriad Genetics (MYGN) announced the publication of the analytical validation for their FirstGene Multiple Prenatal Screen in Clinical Chemistry journal, showing high sensitivity and specificity for detecting various conditions. The company, a molecular diagnostics firm with a market cap of $398.96 million, faces financial challenges despite this advancement, including negative earnings and declining revenue per share. While its P/S ratio suggests undervaluation, Myriad Genetics' financial health and high volatility present risks.
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
Myriad Genetics announced the publication of the analytical validation for its FirstGene Multiple Prenatal Screen in Clinical Chemistry, confirming high sensitivity and specificity for each component. The study, involving nearly 500 samples, demonstrated the test's ability to accurately screen for fetal aneuploidy, RhD compatibility, and 19 prevalent recessive conditions. The FirstGene screened is designed as an integrated solution to streamline prenatal genetic risk assessment and is currently undergoing further evaluation in the CONNECTOR study.
Myriad Genetics Publishes Analytical Validation Results for FirstGene® Multiple Prenatal Screen
Myriad Genetics announced the publication of analytical validation results for its FirstGene® Multiple Prenatal Screen in Clinical Chemistry, showing high sensitivity (≥98.2%) and specificity (≥99.0%). This integrated test aims to streamline prenatal genetic risk assessment by combining analyses for fetal aneuploidy, RhD compatibility, and recessive conditions from a single maternal blood sample. The FirstGene screen is currently being evaluated in a prospective clinical study called CONNECTOR to establish its clinical validity and utility before commercialization.
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
Myriad Genetics announced the publication of an analytical validation study for its FirstGene Multiple Prenatal Screen in Clinical Chemistry. The study, involving nearly 500 samples, demonstrated that each component of the test achieved exceptional analytical sensitivity (≥98.2%) and specificity (≥99.0%) for aneuploidy, recessive single-gene conditions, and fetomaternal blood compatibility. This comprehensive validation supports the accuracy and reproducibility of the FirstGene screen, positioning it for broad commercialization as an integrated prenatal genetic risk assessment solution.
United States Cancer Biomarker Market is Going to Boom | Merck KGaA • QIAGEN • Illumina • Myriad Genetics
Coherent Market Insights has released a comprehensive report on the United States Cancer Biomarker Market, forecasting its growth from 2026-2033. The report analyzes market trends, competition, geographic distribution, and identifies key players such as Roche, Thermo Fisher Scientific, and Illumina. It also outlines market segmentation for diagnostics, prognostics, therapeutics, and personalized medicine, providing insights for stakeholders.
Ahead of Myriad (MYGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Myriad Genetics (MYGN) is expected to report a Q4 quarterly loss of -$0.02 per share, a 166.7% year-over-year decline, with revenues anticipated to be down 1.4% to $207.59 million. Analysts are closely watching key metric estimates, including revenues for Prenatal ($47.02M, +4.7%), Hereditary Cancer ($94.87M, +0.6%), Pharmacogenomics ($36.87M, -9.2%), and Tumor Profiling ($28.59M, -7.2%). The company currently holds a Zacks Rank #4 (Sell), suggesting potential underperformance.
Myriad Genetics to Host Fourth Quarter and Full Year 2025 Earnings Conference Call on February 23, 2026
Myriad Genetics, Inc. will host its fourth quarter and full year 2025 earnings conference call on February 23, 2026, at 4:30 pm ET, following the release of financial results after market close. The call will offer vital insights into the company's performance, and a live webcast will be accessible on Myriad's Investor Relations website. Additionally, key executives will be presenting at several upcoming investor healthcare conferences to engage with investors and stakeholders.
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
Myriad Genetics, Inc. announced it will release its fourth quarter and full year 2025 financial results on Monday, February 23, 2026, after the market closes, followed by an earnings conference call. The company's management will also participate in three upcoming investor healthcare conferences in March 2026. These events include fireside chats at the TD Cowen 46th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference, as well as 1-on-1 meetings at the Barclays 28th Annual Global Healthcare conference.
Myriad Genetics (MYGN) Projected to Post Earnings on Monday
Myriad Genetics (NASDAQ: MYGN) is expected to report its Q4 2025 earnings before market open on Monday, February 23rd, with analysts projecting a loss of $0.02 per share. The stock has shown recent weakness, trading below its 50- and 200-day moving averages, and institutional investors have made adjustments to their holdings. Wall Street sentiment remains mixed, with a consensus "Hold" rating and an average price target of $9.44.
Little Excitement Around Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues As Shares Take 27% Pounding
Myriad Genetics, Inc. (NASDAQ:MYGN) shares have dropped 27% in the past month, contributing to a 69% decline over the last year. The company's low price-to-sales (P/S) ratio of 0.5x, significantly below the biotech industry average, reflects investor pessimism due to uninspiring revenue growth and a forecast of 5.0% annual revenue climb, which is materially lower than the broader industry's 135% forecast. This analysis suggests the depressed P/S ratio is justified by the company's weak revenue outlook.
Myriad Genetics showcases prenatal screening breakthroughs at major conference
Myriad Genetics will present its pioneering advancements in prenatal screening at the Annual Pregnancy Meeting, hosted by the Society for Maternal-Fetal Medicine. The presentation will spotlight the efficacy of pcfDNA screening with fetal fraction amplification in early pregnancy (8-10 weeks), backed by data from over 28,000 samples. This initiative aims to provide valuable insights to attendees in the field.
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Rating of "Hold" by Brokerages
Myriad Genetics, Inc. (NASDAQ:MYGN) has received a consensus "Hold" rating from thirteen brokerage firms, with an average 12-month target price of $9.44. While institutional ownership is high, analyst actions have been mixed, with some firms raising price targets and others issuing downgrades. The company, which specializes in hereditary cancer and other genetic tests, currently trades around $5.29 per share with a market capitalization of $493.08 million.
Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?
Myriad Genetics (NASDAQ:MYGN) has increased its debt to US$119.5m, but maintains a net cash position of US$25.9m. Despite current liabilities exceeding short-term assets by US$91.9m and ongoing losses, the company's market capitalization of US$509.9m and net cash provide a buffer for continued operations, though it is considered somewhat risky due to negative free cash flow.
Responsive Playbooks and the MYGN Inflection
The article analyzes Myriad Genetics Inc. (NASDAQ: MYGN), highlighting weak sentiment across all horizons which supports a short bias. It details three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, showing resistance being tested with exceptional risk-reward for short setups. The report suggests a potential 39.1% downside with minimal risk if resistance holds.
Parp Inhibitor Biomarkers Market Generated Opportunities, Future Scope 2026-2033 |Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Invitae Corporation
A new report by Coherent Market Insights details the opportunities within the Parp Inhibitor Biomarkers Market for the period 2026-2033. The study offers insights into market structure, segmentation by product type, application, and region, and profiles leading companies like Myriad Genetics Inc. and F. Hoffmann-La Roche AG. It aims to provide decision-makers with actionable intelligence to navigate the evolving market landscape.
Myriad Genetics to launch Precise MRD cancer test in March 2026
Myriad Genetics (NASDAQ:MYGN) announced it will launch its Precise MRD cancer detection test in March 2026, starting with breast cancer patients and expanding to colorectal and renal cancers later that year. The test, designed to detect circulating tumor DNA at ultrasensitive levels, has shown promising initial results with high baseline sensitivity in breast and colorectal cancer patients. Despite its stock trading below its 52-week high, the company is considered undervalued by InvestingPro, with strong financial projections for 2025 and 2026.
Myriad Genetics Announces Commercial Launch of Precise MRD™ Assay for Enhanced Cancer Detection and Monitoring
Myriad Genetics has announced the commercial launch roadmap for its Precise MRD™ assay, an ultra-sensitive test for circulating tumor DNA (ctDNA) designed to improve cancer detection and monitoring. The assay will initially launch for breast cancer in March 2026, with plans to expand to colorectal and renal cancers later in the year, and potentially ovarian and endometrial cancers in 2027. Clinical data presented at major oncology conferences highlight the assay's high sensitivity and effectiveness in predicting recurrence and monitoring treatment response.
Myriad cancer DNA test detects signals at 1-in-a-million
Myriad Genetics announced a limited clinical launch for its Precise MRD cancer DNA test in March 2026, starting with breast cancer and expanding to colorectal and renal cancers later the same year. The test demonstrates ultrasensitive detection down to 1 part-per-million, with studies showing high baseline sensitivity and strong recurrence prediction capabilities. This move reinforces Myriad's focus on precision oncology, aiming for earlier insights and improved patient outcomes.
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
Myriad Genetics announced its commercialization roadmap for the Precise MRD™ assay, planning a limited clinical launch in March 2026 for breast cancer, expanding to colorectal and renal cancers later the same year, and potentially to ovarian and endometrial cancers in 2027. This initiative is supported by new study data demonstrating the assay's high sensitivity in detecting circulating tumor DNA (ctDNA) and its strong correlation with clinical outcomes in breast and colorectal cancers. The company aims to advance precision oncology by providing earlier insights and more informed treatment decisions for patients through ultrasensitive MRD testing.
Carrier Screening Market with Insights from Abbott
The Carrier Screening market is experiencing substantial growth due to advancements in genetic testing and increased awareness of reproductive health. Key players like Abbott Laboratories, Myriad Genetics, and Illumina are driving innovation. The market is segmented by molecular and biochemical screening tests, and applications across hospitals, clinics, and ambulatory surgical centers.
2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm
This article analyzes three healthcare stocks: Myriad Genetics (MYGN), Cardinal Health (CAH), and Merck (MRK). It advises selling MYGN due to slow revenue growth and negative returns, while recommending CAH and MRK for their strong market positions, growing revenues, and solid financial performance. The article highlights the importance of durable advantages in the competitive healthcare sector.
Myriad Genetics (NASDAQ:MYGN) Downgraded by Zacks Research to Strong Sell
Zacks Research has downgraded Myriad Genetics (NASDAQ:MYGN) from a "hold" to a "strong sell" rating. Despite this, the stock retains a consensus "Hold" rating from other analysts with a price target of $9.44. The company's shares opened at $5.68, down 4.1%, and currently have a market capitalization of approximately $529 million.
Myriad Genetics (NASDAQ:MYGN) Stock Price Down 6.5% - Time to Sell?
Myriad Genetics (NASDAQ:MYGN) shares dropped 6.5% on Tuesday, trading at $5.5360 on lower-than-average volume. The company has a "Hold" consensus rating from analysts with an average price target of $9.44, though recent analyst actions are mixed. Institutional ownership stands at approximately 99%, with several funds increasing their stakes in the fourth quarter.
Myriad Genetics, Inc. (MYGN) Stock Analysis: Uncovering a 36.50% Potential Upside in the Diagnostics Sector
Myriad Genetics, Inc. (MYGN) presents a potential 36.50% upside in the diagnostics sector, according to analyst ratings, despite current valuation challenges and revenue decline. The company specializes in molecular diagnostic testing and precision medicine, with strategic collaborations aiming to boost market share. Investors are watching to see if initiatives can overcome financial headwinds and drive growth.
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
Myriad Genetics (NASDAQ: MYGN) has announced preliminary financial results for Q4 and full-year 2025, expecting total revenues between $207-$209 million for Q4 and $822-$824 million for the full year. The company also provided full-year 2026 financial guidance, projecting revenues between $860-$880 million, an adjusted gross margin of 68%-69%, and adjusted EBITDA of $37-$49 million. These preliminary results and guidance will be discussed at the 44th Annual J.P. Morgan Healthcare Conference.
MYRIAD GENETICS Q4 2025 Earnings Preview: Recent $MYGN Insider Trading, Hedge Fund Activity, and More
This article provides a preview of MYRIAD GENETICS (MYGN) Q4 2025 earnings, expected on January 15th, with analysts forecasting $210,962,132 in revenue and -$0.02 EPS. It details recent hedge fund activity, showing both increased and decreased positions, and notes $14,994 in government contract awards. Analyst ratings are largely positive, with a median price target of $8.25 from four analysts.
Myriad Genetics Reports Preliminary Q4 Revenue; Issues 2026 Guidance
Myriad Genetics, Inc. announced preliminary fourth-quarter revenue expectations of $207 million to $209 million, leading to a projected full-year 2025 revenue between $822 million and $824 million. The company also provided guidance for full-year 2026, anticipating revenue between $860 million and $880 million, and adjusted EBITDA in the range of $37 million to $49 million. Actual Q4 results will be released in February 2026.
Myriad Genetics forecasts 2026 revenue growth of 6% to $870 million
Myriad Genetics announced preliminary unaudited financial results for 2025, projecting revenues between $207 million and $209 million for Q4 2025 and $822 million to $824 million for the full year. For 2026, the company forecasts revenue growth of approximately 6% to $860 million-$880 million, alongside an adjusted gross margin of 68%-69% and a 43% increase in adjusted EBITDA midpoint. These results will be discussed further at the 44th Annual J.P. Morgan Healthcare Conference.
Myriad Genetics Announces Select Preliminary Fourth Quarter
Myriad Genetics, Inc. announced preliminary financial results for the fourth quarter and full year 2025, expecting total revenues of $207-$209 million and $822-$824 million, respectively. The company also introduced its full-year 2026 financial guidance, projecting revenues between $860-$880 million, an adjusted gross margin of 68%-69%, and adjusted EBITDA of $37-$49 million. These preliminary results and guidance will be discussed further at the 44th Annual J.P. Morgan Healthcare Conference.
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
Myriad Genetics (NASDAQ: MYGN) announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, expecting total revenues between $207-$209 million for Q4 and $822-$824 million for the full year 2025. The company also introduced its full-year 2026 financial guidance, projecting revenues between $860-$880 million, adjusted gross margin of 68%-69%, and adjusted EBITDA of $37-$49 million. These preliminary results and guidance will be discussed further at the 44th Annual J.P. Morgan Healthcare Conference.
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Hold" from Analysts
MarketBeat reports that fourteen analysts have issued an average "Hold" recommendation for Myriad Genetics, Inc. (NASDAQ:MYGN), with an average 12-month target price of $10.50. Despite remaining unprofitable with an EPS of ($0.19) and a negative net margin, institutional ownership is notably high at 99.02%, and several institutions have significantly increased their positions. The company's stock currently trades around $6.58, with a market capitalization of $613.35 million.
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
Myriad Genetics, Inc. announced that its president and CEO, Sam Raha, will speak at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 5:15 pm PT. The presentation will be accessible via a live webcast on the company's investor relations website. Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, focusing on tests that assess disease risk and guide treatment decisions.
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
Myriad Genetics, Inc. (NASDAQ: MYGN) announced that its president and CEO, Sam Raha, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14th at 5:15 pm PT. The presentation will be available via live webcast and archived on the company's investor relations website. Myriad Genetics is a leading molecular diagnostic testing and precision medicine company.
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
Myriad Genetics, a leader in molecular diagnostic testing, announced that its President and CEO, Sam Raha, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 5:15 p.m. PT. A live webcast and archive of the presentation will be available on the company's investor relations website. The company focuses on developing molecular tests to assess disease risk and guide treatment decisions.
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
Myriad Genetics, Inc. announced that its president and CEO, Sam Raha, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will cover the company's work in molecular diagnostic testing and precision medicine. A live webcast and archived version of the presentation will be available on the company's investor relations website.
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
Myriad Genetics, a leader in molecular diagnostic testing and precision medicine, announced that its president and CEO, Sam Raha, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will be webcast live and archived on the company's investor relations website. Myriad Genetics develops molecular tests to assess disease risk, progression, and guide treatment decisions to improve patient care and reduce healthcare costs.
The Truth About Myriad Genetics Inc: Is This DNA Stock a Sleeper Goldmine or Just Overhyped?
This article examines Myriad Genetics Inc (MYGN), a company focused on DNA testing for health risks and personalized medicine. It discusses the social media buzz around DNA testing and evaluates whether the stock is a worthwhile investment or merely overhyped, considering its business model, volatile performance, and high-risk nature. The author concludes that MYGN is a speculative cop for high-risk, thesis-driven investors who believe in DNA-driven medicine, rather than casual investors.
Precision Trading with Myriad Genetics Inc. (MYGN) Risk Zones
This article discusses precision trading strategies for Myriad Genetics Inc. (MYGN), highlighting a weak sentiment across all time horizons that supports a short bias. It details an exceptional risk-reward setup targeting a 53.4% gain versus a 0.2% risk and outlines three distinct AI-generated trading strategies tailored to different risk profiles. The strategies include position trading, momentum breakout, and risk hedging, complete with entry zones, targets, and stop losses.
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why
Myriad Genetics (NASDAQ:MYGN) saw its shares jump 3.7% after signing an exclusive agreement with Zydus Lifesciences to commercialize three of its cancer tests in India. This partnership aims to expand precision oncology services for Indian patients and grow Myriad's international presence. The stock's performance reflects market recognition of this significant international expansion, despite its high volatility and a year-to-date decline of 49.7%.
Zydus Lifesciences signs deal with Myriad Genetics for cancer-risk assessment diagnostic tests
Zydus Lifesciences has partnered with Myriad Genetics to offer cancer-risk assessment diagnostic tests in India. This collaboration aims to provide advanced genetic testing to help individuals understand their hereditary cancer risks, facilitating timely intervention and personalized care. The initiative strengthens Zydus's presence in the diagnostics sector.
Myriad wins UPC ruling as GXD-Bio breast cancer patent is revoked
The Unified Patent Court (UPC) has revoked GXD-Bio's breast cancer testing patent, dismissing infringement claims against Myriad's EndoPredict test. This ruling clears the way for Myriad to continue marketing its breast cancer test in Europe. The South Korean biotech company GXD-Bio lost its infringement action against the American genetic testing firm Myriad Genetics and its European affiliates.
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why
Myriad Genetics (NASDAQ:MYGN) saw its stock jump 3.7% after signing an exclusive agreement with Zydus Lifesciences to commercialize three of its cancer tests in India. This partnership aims to expand precision oncology services and improve diagnosis and treatment planning for Indian patients. For Myriad, the deal represents a key step in expanding its international market presence.
Zydus Lifesciences Ties Up With Myriad Genetics to Bring Advanced Cancer-Risk Tests to India
Zydus Lifesciences has partnered with US-based Myriad Genetics to exclusively launch advanced cancer-risk assessment and prognostic diagnostic tests in India. This collaboration will introduce tests like MyRisk Hereditary Cancer Test, MyChoice HRD Plus, and Prolaris, aiming to expand precision oncology access. The initiative seeks to improve diagnosis, predict disease progression, and enable personalized treatment plans for cancer patients across India.
Zydus Signs Exclusive Pact with US-Based Myriad Genetics to Launch Cancer Diagnostic Tests in India
Zydus Lifesciences has partnered with Myriad Genetics to introduce advanced cancer-risk assessment and prognostic diagnostic tests in India. This collaboration aims to provide personalized cancer care by offering tests like MyRisk® Hereditary Cancer Test, MyChoice® HRD Plus, and Prolaris® prostate cancer prognostic test. These tests are designed to identify hereditary cancer risks, assess disease progression, and guide treatment decisions, thereby improving patient outcomes in various cancers.
Myriad Genetics, Inc. $MYGN Stake Reduced by Camber Capital Management LP
Camber Capital Management LP significantly reduced its stake in Myriad Genetics, Inc. ($MYGN) by 14.9% in the second quarter, selling 350,000 shares and now holding 2,000,000 shares. This position now constitutes 1.0% of Camber's portfolio. Other institutional investors also adjusted their holdings in Myriad Genetics, which currently has a market capitalization of $680.43 million, a "Hold" consensus rating from analysts, and an average price target of $10.50.
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
Myriad Genetics will present eight abstracts at the 2025 San Antonio Breast Cancer Symposium, focusing on new data for its Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test. The presentations will highlight advances in molecular diagnostic testing, including ultrasensitive ctDNA testing, and their impact on guideline-driven treatment decisions for breast cancer patients. The company aims to showcase its commitment to the cancer care continuum through various studies on germline testing, somatic testing, and polygenic risk assessment.
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
Myriad Genetics announced it will present eight abstracts at the 2025 San Antonio Breast Cancer Symposium (SABCS), focusing on advancements in the Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test. The data highlights the benefits of ultra-sensitive and quantitative ctDNA testing, as well as germline and somatic testing, and polygenic risk assessment in breast cancer. Myriad will also sponsor a session discussing the evolving role of tumor genomic and germline testing.
Why Myriad Genetics (MYGN) Stock Is Up Today
Shares of Myriad Genetics jumped 2.5% after the company announced it would present new data from eight studies at the 2025 San Antonio Breast Cancer Symposium, focusing on advances in its MyRisk® Hereditary Cancer Test and Precise® Molecular Residual Disease (MRD) Test. The research supports treatment decisions, especially for breast cancer, with an executive noting "very strong data." Despite this, the stock has been volatile and is down 46% since the beginning of the year, having recently dropped due to the FDA approval of a competing prostate cancer test.
